Table 2.
CSF concentrations of cytokines correlating with GCL HRF count.
| ONIND | G-HRFlow | G-HRFhigh | ONIND vs. G-HRFlow (p-value)# | ONIND vs. G-HRFhigh (p-value)# | G-HRFlow vs. G-HRFhigh (p-value)# | |
|---|---|---|---|---|---|---|
| Disease duration at CSF (m) | n.a. | 3.3 ± 3.9 | 3.7 ± 4.3 | n.a. | n.a. | 0.6 |
| EDSS | n.a. | 2.0 (1.0-2.5) | 2.0 (1.0-3.0) | n.a. | n.a. | 0.3 |
| Brain MRI gad+ (%) | n.a. | 40.0% | 37.5% | n.a. | n.a. | 1.0 |
| Spinal cord MRI gad+ (%) | n.a. | 30.0% | 12.5% | n.a. | n.a. | 1.0 |
| Radiological activity (%) | n.a. | 50.0% | 37.5% | n.a. | n.a. | 1.0 |
| Clinical activity (%) | n.a. | 60.0% | 37.5% | n.a. | n.a. | 0.7 |
| Disease activity (%) | n.a. | 80.0% | 62.5% | n.a. | n.a. | 1.0 |
| IL1-Ra (pg/mL) | 147.5 ± 51.8 | 164.1 ± 61.4 | 95.1 ± 21.8 | >0.999 | 0.0681 | 0.0244 |
| IL-9 (pg/mL) | 7.0 ± 2.6 | 8.0 ± 4.4 | 4.6 ± 1.5 | >0.999 | 0.0789 | 0.0281 |
| IL-15 (pg/mL) | 32.4 ± 14.7 | 34.2 ± 12.5 | 20.6 ± 9.4 | >0.999 | 0.1187 | 0.0946 |
| G-CSF (pg/mL) | 14.6 ± 5.3 | 16.8 ± 11.6 | 9.6 ± 3.9 | >0.999 | 0.0095 | 0.0249 |
| IFN-γ (pg/mL) | 2.9 ± 1.2 | 2.8 ± 1.0 | 2.2 ± 0.6 | >0.999 | 0.4621 | 0.5566 |
NIND, other not inflammatory neurological diseases; G-HRFlow, RRMS patients with GCL HRF count ≤8.5; G-HRFhigh, RRMS patients with GCL HRF count >8.5; #p-values from Kruskal-Wallis test corrected with multiple comparison Dunn’s test; n.a., not applicable.